Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NKTX

NKTX - Nkarta Inc Stock Price, Fair Value and News

$2.46-0.08 (-3.15%)
Market Closed

60/100

NKTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

60/100

NKTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.94

Target 3M

$2.6

Target 6M

$2.71

NKTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NKTX Price Action

Last 7 days

11.8%

Last 30 days

33.0%

Last 90 days

18.3%

Trailing 12 Months

4.7%

NKTX RSI Chart

NKTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NKTX Valuation

Market Cap

174.7M

Price/Earnings (Trailing)

-1.7

Price/Sales (Trailing)

7.41

Price/Free Cashflow

-1.87

NKTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.94

Target 3M

$2.6

Target 6M

$2.71

NKTX Fundamentals

NKTX Revenue

Revenue (TTM)

18.8M

Rev. Growth (Yr)

-29.36%

Rev. Growth (Qtr)

-6.37%

NKTX Earnings

Earnings (TTM)

-102.6M

Earnings Growth (Yr)

23.39%

Earnings Growth (Qtr)

5.49%

NKTX Profitability

Return on Equity

-30.37%

Return on Assets

-24.02%

Free Cashflow Yield

-53.54%

NKTX Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

-1.34

NKTX Alerts

  • CITADEL ADVISORS LLC reported owning 4.5% of NKTX [2024-12-13]

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202518.8M000
202413.9M16.0M17.9M0
202309.0M12.0M13.5M
2022372.0K954.0K2.8M5.6M
2021327.3K341.5K355.8K370.0K
2020306.3K308.5K310.8K313.0K
2019000304.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Nkarta Inc

NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
 CEO
 WEBSITEnkartatx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES169

Nkarta Inc Frequently Asked Questions

NKTX is the stock ticker symbol of Nkarta Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Nkarta Inc is 174.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NKTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether NKTX is over valued or under valued. Whether Nkarta Inc is cheap or expensive depends on the assumptions which impact Nkarta Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTX.

As of Wed Jan 28 2026, NKTX's PE ratio (Price to Earnings) is -1.7 and Price to Sales (PS) ratio is 7.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTX PE ratio will change depending on the future growth rate expectations of investors.